Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 373.30M | 358.71M | 310.46M | 331.34M | 391.87M | 336.79M |
Gross Profit | 322.35M | 322.11M | 261.06M | 317.55M | 378.03M | 335.01M |
EBITDA | 4.16M | 99.45M | 248.96M | 322.25M | 478.18M | 386.42M |
Net Income | -59.72M | 23.39M | 179.72M | 213.92M | 368.84M | 224.40M |
Balance Sheet | ||||||
Total Assets | 1.25B | 1.30B | 1.24B | 1.23B | 926.39M | 999.57M |
Cash, Cash Equivalents and Short-Term Investments | 446.88M | 412.50M | 193.51M | 291.05M | 201.53M | 246.49M |
Total Debt | 451.26M | 451.10M | 449.08M | 637.88M | 394.65M | 385.52M |
Total Liabilities | 607.49M | 609.90M | 568.55M | 665.71M | 400.46M | 391.73M |
Stockholders Equity | 646.90M | 691.16M | 674.96M | 565.79M | 414.74M | 539.91M |
Cash Flow | ||||||
Free Cash Flow | 195.99M | 188.42M | 140.65M | 201.66M | 362.51M | 313.10M |
Operating Cash Flow | 200.26M | 188.69M | 141.06M | 201.73M | 363.81M | 313.11M |
Investing Cash Flow | -55.42M | -63.79M | -66.76M | -56.63M | 43.72M | -314.94M |
Financing Cash Flow | -4.11M | -13.45M | -171.84M | -55.57M | -452.50M | -29.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $1.01B | 27.12 | 11.23% | ― | 29.20% | ― | |
66 Neutral | $1.74B | ― | -60.96% | ― | 8.61% | 35.36% | |
62 Neutral | $1.00B | ― | -36.26% | ― | 127.33% | 21.31% | |
61 Neutral | $1.09B | 2.55 | 30.06% | ― | 25.92% | ― | |
59 Neutral | £5.93B | 9.05 | -57.69% | 4.70% | 15.15% | -8.16% | |
57 Neutral | $1.24B | 89.44 | -8.84% | ― | 17.90% | -133.73% | |
52 Neutral | $1.41B | ― | -23.20% | ― | 24.49% | 5.14% |
At the Annual Meeting of Stockholders on May 19, 2025, Innoviva, Inc. elected five board members for a one-year term and approved executive compensation on a non-binding advisory basis. Additionally, stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (INVA) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Innoviva stock, see the INVA Stock Forecast page.